Biomarker bei HNSCC und die Rolle der Immunonkologie

Immunonkologika gehören zu den potentesten Medikamenten bei Patienten mit Kopf-Hals-Tumoren. Aber nach wie vor ist es nur ein relativ kleiner Prozentsatz an Patienten, der davon profitiert. Wir werfen einen Blick auf die Hintergründe und gehen der Frage nach, was Biomarker bei der Patientenselektion leisten können.

Publication History

Article published online:
07 October 2020

• Literatur

• 1 Vesely MD, Kershaw MH, Schreiber RD. et al. Natural innate and adaptive immunity to cancer. Ann Rev Immunol 2011; 29: 235271
• 2 Alexandrov LB, Nik-Zainal S, Wedge DC. et al. Signatures of mutational processes in human cancer. Nature 2013; 500: 415-421
• 3 Hodi FS, O’Day SJ, McDermott DF. et al. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. N Engl J Med 2010; 363: 711-723
• 4 Maio M, Grob JJ, Aamdal S. et al. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol 2015; 33: 1191-1196
• 5 Wolchok JD, Chiarion-Sileni V, Gonzalez R. et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med 2017; 377: 1345-1356
• 6 Schildhaus HU. Der prädiktive Wert der PD-L1-Diagnostik. Pathologe 2018; 39: 498-519
• 7 Haddad RI, Seiwert TY, Chow LQM. et al. Genomic determinants of response to pembrolizumab in head and neck squamous cell carcinoma. J Clin Oncol 2017; 35 (Suppl. 15) 6009
• 8 Weichert W. Molekulare Prädiktoren in der Immunonkologie. Pathologe 2018; 39: 546-555
• 9 Legrand FA, Gandara DR, Mariathasan S. et al. Association of high TMB and atezolizumab-efficacy across multiple tumor types. J Clin Oncol 2018; 39 (Suppl. 15) 12000
• 10 Allgäuer M, Budczies J, Christopoulos P. et al. Implementing tumor mutational burden (TMB) analysis in routine diagnostics – a primer for molecular pathologists and clinicians. Transl Lung Cancer Res 2018; 7: 703-715
• 11 Kim ES, Velcheti V, Mekhail T. et al. Primary efficacy results from B-F1RST, a prospective Phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC). ESMO 2018; LBA55
• 12 Davoli T, Uno H, Wooten C. et al. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science 2017; 355: eaaf8399
• 13 Roh W, Chen PL, Reuben A. et al. Integrated molecular anlysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Trans Led 2017; 9: eaah3560
• 14 Karachaliou N, Gonzalez-Cao M, Crespo G. et al. Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients. Adv Med Oncol 2018; 10: 1758834017749748
• 15 Yoo SH, Keam B, Ock CY. et al. Prognostic value of the association between MHC class I downregulation and PD-L1 upregulation in head and neck squamous cell carcinoma patients. Nature Sci Rep 2019; 9: 7680